1-9 of 9
Helen Varsos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Jens Hillengass, Adam D. Cohen, Mounzer E Agha, Michel Delforge, Tessa Kerre, Wilfried Roeloffzen, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab, Christof Scheid, Sebastien Anguille, Pieter Sonneveld, Sonja Zweegman, Jordan M. Schecter, Kevin C De Braganca, Carolyn Chang Jackson, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Tzu-min Yeh, Pankaj Mistry, Tito Roccia, Qingxuan Song, Muhammad Akram, Octavio Costa Filho, Dong Geng, Yael C. Cohen, Niels W.C.J. Van De Donk
Journal: Blood
Blood (2023) 142 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2023-178882
Published: 2023
Journal Articles

Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)

Niels W.C.J. Van De Donk, Surbhi Sidana, Jordan M. Schecter, Carolyn Chang Jackson, Nikoletta Lendvai, Kevin C De Braganca, Ana Slaughter, Carolina Lonardi, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Shirin Jadidi, Junchen Gu, Hao Zhao, Katherine Li, Erin Lee, Loreta Marquez, Man Zhao, Tzu-min Yeh, Diana Chen, Erika Florendo, Nitin Patel, Muhammad Akram, Jaime Gellego Perez-Larraya, Paula Rodriguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 3501.
https://doi.org/10.1182/blood-2023-178743
Published: 2023
Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Clinical Trials & Observations
Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W. C. J. van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C. De Braganca, Christina Corsale, Jordan M. Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesus San-Miguel
Journal: Blood
Blood (2023) 141 (3): 219–230.
https://doi.org/10.1182/blood.2022015526
Published: 2023
Includes: Supplemental data
Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Niels WCJ Van De Donk, Mounzer Agha, Adam D Cohen, Yael C Cohen, Sébastien Anguille, Tessa Kerre, Wilfried W.H. Roeloffzen, Jordan M Schecter, Kevin C De Braganca, Carolyn C Jackson, Helen Varsos, Pankaj Mistry, Tito Roccia, Xiaoying Xu, Katherine Li, Enrique Zudaire, Christina Corsale, Muhammad Akram, Dong Geng, Lida Pacaud, Pieter Sonneveld, Sonja Zweegman
Journal: Blood
Blood (2022) 140 (Supplement 1): 7536–7537.
https://doi.org/10.1182/blood-2022-159169
Published: 2022
Journal Articles

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez Otero, Bruno Paiva, Niels W.C.J. Van De Donk, Thomas Martin, Attaya Suvannasankha, Christina Corsale, Jordan M. Schecter, Kevin C. De Braganca, Carolyn C. Jackson, Helen Varsos, William Deraedt, Tito Roccia, Pankaj Mistry, Xiaoying Xu, Katherine Li, Enrique Zudaire, Muhammad Akram, Lida Pacaud, Irit Avivi, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4646–4648.
https://doi.org/10.1182/blood-2022-158563
Published: 2022
Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Yael C. Cohen, Adam D Cohen, Michel Delforge, Jens Hillengass, Hartmut Goldschmidt, Katja Weisel, Marc-Steffen Raab, Christof Scheid, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Tzu-min Yeh, Liwei Wang, Martin Vogel, Christina Corsale, Muhammad Akram, Lida Pacaud, Tonia Nesheiwat, Mounzer Agha, Hermann Einsele
Journal: Blood
Blood (2021) 138 (Supplement 1): 3866.
https://doi.org/10.1182/blood-2021-146072
Published: 2021
Journal Articles

CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

Niels W.C.J. Van de Donk, Michel Delforge, Mounzer Agha, Adam D Cohen, Yael C Cohen, Jens Hillengass, Sebastien Anguille, Tessa Kerre, Wilfried Roeloffzen, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Liwei Wang, Martin Vogel, Enrique Zudaire, Christina Corsale, Muhammad Akram, Dong Geng, Tonia Nesheiwat, Lida Pacaud, Pieter Sonneveld, Sonja Zweegman
Journal: Blood
Blood (2021) 138 (Supplement 1): 2910.
https://doi.org/10.1182/blood-2021-146074
Published: 2021
Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux
Journal: Blood
Blood (2018) 132 (Supplement 1): 463.
https://doi.org/10.1182/blood-2018-99-114877
Published: 2018
Journal Articles

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Pierre Fenaux, MD PhD, Azra Raza, MD, Edo Vellenga, MD, Uwe Platzbecker, MD, Valeria Santini, MD, Irina Samarina, MD, Koen Van Eygen, MD, Maria Díez-Campelo, MD PhD, Mrinal M. Patnaik, MDMBBS, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Aleksandra Rizo, MD PhD, David P. Steensma, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4256.
https://doi.org/10.1182/blood.V130.Suppl_1.4256.4256
Published: 2017